1. Home
  2. SRRK vs PSN Comparison

SRRK vs PSN Comparison

Compare SRRK & PSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

N/A

Current Price

$56.23

Market Cap

6.8B

Sector

Health Care

ML Signal

N/A

Logo Parsons Corporation

PSN

Parsons Corporation

N/A

Current Price

$48.84

Market Cap

6.3B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SRRK
PSN
Founded
2012
1944
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
6.3B
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SRRK
PSN
Price
$56.23
$48.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
13
Target Price
$56.17
$79.18
AVG Volume (30 Days)
981.1K
2.0M
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.77
EPS
N/A
0.49
Revenue
N/A
$6,364,245,000.00
Revenue This Year
N/A
$5.87
Revenue Next Year
$534.24
$7.61
P/E Ratio
N/A
$94.00
Revenue Growth
N/A
N/A
52 Week Low
$27.07
$36.26
52 Week High
$58.49
$89.50

Technical Indicators

Market Signals
Indicator
SRRK
PSN
Relative Strength Index (RSI) 62.50 48.34
Support Level $45.81 $48.16
Resistance Level $58.49 $49.32
Average True Range (ATR) 2.38 1.71
MACD 0.63 0.20
Stochastic Oscillator 93.21 85.25

Price Performance

Historical Comparison
SRRK
PSN

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

Share on Social Networks: